Diet soda drinkers seemingly unfazed by aspartame report

 

The World Health Organization's (WHO) July report calling aspartame "possibly carcinogenic" didn't fizz out the love for diet sodas, HundredX data featured in Food Dive reveals.


HundredX’s analysis, which aggregated 150,000 pieces of customer feedback, gauged consumer reactions towards diet soda brands such as Coke, Pepsi, and Dr. Pepper following the WHO’s announcement. Bucking expectations, Consumption Intent for diet sodas rose by 2% from May through August, surpassing the modest 1% rise seen in regular sodas.

HundredX’s Vice President of Strategy, Andre Benjamin, shared with Food Dive that consumers often value taste and other happiness-contributing factors more than the potential health risks associated with aspartame. HundredX analysis found that the majority of diet soda drinkers perceive their drink of choice to be healthier than regular soda, a sentiment that hasn’t wavered since the WHO’s report.

Read our full exploration on diet soda sentiments here: Soda Drinkers Unmoved by Aspartame Concerns (hundredx.com)

Crowd-Powered Business Advantage


Leveraging the power of The Crowd, HundredX continuously monitors consumer perceptions, providing businesses with essential information to maintain their market position. We tap into real consumer feedback to understand industry trends like fast fashion, as one example. With our extensive coverage of 80+ industries and 3,000+ brands, we analyze the collective opinions of everyday customers to uncover what really matters to them. Moreover, we evaluate how their priorities influence purchasing decisions and attitudes towards businesses. These insights empower business leaders to craft customer-focused strategies and gain a competitive edge in their markets.


Please contact our team for a deeper look at HundredX's non-alcoholic beverage data, which includes more than 400,000 pieces of customer feedback across 91 brands.

Share This Article

Starbucks shows weakness as consumers feel worse about taste

06 May, 2024
Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.

Forbes Announces Best Brands for Social Impact List 2024 Powered by HundredX

06 May, 2024
Forbes Best Brands for Social Impact, Powered by HundredX

Mounjaro maintains top spot among GLP-1 drugs

06 May, 2024
Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers. GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound). HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price. Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find: GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less . Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range. Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get . Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.
Share by: